How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Human Use Rabies Vaccine Market
- By Vaccine Type: Cell Culture Vaccines, Purified Chick Embryo Cell Vaccine (PCECV), Human Diploid Cell Vaccine (HDCV), Vero Cell Rabies Vaccine, Nerve Tissue Vaccine
- By Indication: Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP)
- By Route of Administration: Intramuscular (IM), Intradermal (ID)
- By End User: Hospitals, Clinics, Public Health Centers, Travel Clinics
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Cell Culture Vaccines leads By Vaccine Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 12 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 258 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.158 →
- 11 Company Profiles 12 players: SWOT & benchmarking p.166 →
Full report · locked preview
Everything inside the Human Use Rabies Vaccine Market report
A complete, evidence-based study - 11 chapters and 108 sections covering market size, segmentation across 4 axes, regional analysis and 12 company profiles, forecast to 2033.
Segmentation covered
Vaccine Type 5
Indication 2
Route of Administration 2
End User 4
Companies profiled
Sanofi Pasteur
GlaxoSmithKline (GSK)
Bharat Biotech
Serum Institute of India
Merial (now part of Boehringer Ingelheim)
Novartis (now part of Sandoz)
Mundipharma
Zydus Cadila
Shantha Biotechnics (a Sanofi company)
Bio-Med India
Jubilant Biosys
Vaccine manufacturers under the WHO prequalification program for rabies vaccines
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
12 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Sanofi Pasteur
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →GlaxoSmithKline (GSK)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Bharat Biotech
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Serum Institute of India
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Merial (now part of Boehringer Ingelheim)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Novartis (now part of Sandoz)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Mundipharma
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Zydus Cadila
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Shantha Biotechnics (a Sanofi company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Bio-Med India
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Jubilant Biosys
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →Vaccine manufacturers under the WHO prequalification program for rabies vaccines
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,063M by 2033 · 6.6% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Cell Culture Vaccines51.4
- Purified Chick Embryo Cell Vaccine (PCECV)11.7
- Human Diploid Cell Vaccine (HDCV)13.2
- Vero Cell Rabies Vaccine13.9
- Nerve Tissue Vaccine9.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,399M → $2,262M · 6.2%
Europe$974.8M → $1,566M · 6.1%
Asia Pacific$890.0M → $1,317M · 5.0%
Latin America$551.0M → $852.6M · 5.6%
Middle East and Africa$423.8M → $664.8M · 5.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.542026
6.552027
6.582028
6.572029
6.582030
6.612031
6.612032
6.642033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Sanofi Pasteur16.9
- GlaxoSmithKline (GSK)22.4
- Bharat Biotech10.1
- Serum Institute of India7.1
- Merial (now part of Boehringer Ingelheim)6.8
- Novartis (now part of Sandoz)8.7
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Vaccine Type32.7%
Indication27.8%
Route of Administration20.3%
End User19.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.9
- Europe23.5
- Asia Pacific19.8
- Latin America12.8
- Middle East and Africa10.0
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Sanofi Pasteur | 87 | 98 | 97 | 91 | 78 | 86 | 90 |
| GlaxoSmithKline (GSK) | 85 | 88 | 91 | 72 | 78 | 79 | 82 |
| Bharat Biotech | 68 | 70 | 81 | 83 | 65 | 72 | 73 |
| Serum Institute of India | 82 | 69 | 63 | 66 | 79 | 59 | 70 |
| Merial (now part of Boehringer Ingelheim) | 66 | 56 | 59 | 69 | 67 | 61 | 63 |
| Novartis (now part of Sandoz) | 71 | 56 | 70 | 67 | 64 | 50 | 63 |
| Mundipharma | 48 | 51 | 55 | 63 | 63 | 57 | 56 |
| Zydus Cadila | 57 | 57 | 48 | 56 | 50 | 46 | 52 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Sanofi Pasteur
- GlaxoSmithKline (GSK)
- Bharat Biotech
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Sanofi Pasteur | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| GlaxoSmithKline (GSK) | ◐ | ✓ | ✓ | ◐ | ◐ | ✓ |
| Bharat Biotech | ✓ | ✓ | ✓ | ✓ | − | ✓ |
| Serum Institute of India | ◐ | ◐ | ◐ | − | ◐ | ◐ |
| Merial (now part of Boehringer Ingelheim) | ✓ | ◐ | ◐ | − | ✓ | ◐ |
| Novartis (now part of Sandoz) | ✓ | ◐ | ◐ | − | ◐ | ◐ |
| Mundipharma | − | − | ◐ | − | − | ◐ |
| Zydus Cadila | ◐ | ◐ | − | ◐ | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Sanofi Pasteur90
2GlaxoSmithKline (GSK)82
3Bharat Biotech73
4Serum Institute of India70
5Merial (now part of Boehringer Ingelheim)63
6Novartis (now part of Sandoz)63
7Mundipharma56
8Zydus Cadila52
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Sanofi PasteurGlaxoSmithKline (GSK)
Challenger2
Strong scale, closing on the leaders.
Bharat BiotechSerum Institute of India
Contender2
Focused players with pockets of strength.
Merial (now part of Boehringer Ingelheim)Novartis (now part of Sandoz)
Niche2
Specialists in a single segment or region.
MundipharmaZydus Cadila
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Vaccine Type in North America, then scale across Human Use Rabies Vaccine Market — a $260M beachhead inside a $4.75B market.
Beachhead (SOM)$260Mobtainable near-term
Serviceable (SAM)$1.63Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Cell Culture Vaccines
Best fit — highest urgency & budget in Vaccine Type.
Economic buyer80 fit
Purified Chick Embryo Cell Vaccine (PCECV)
Strong fit — clear ROI and a fast path to value.
End user69 fit
Human Diploid Cell Vaccine (HDCV)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Vaccine Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Indication & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Route of Administration
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel27%
Digital / self-serve20%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Vaccine Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Human Use Rabies Vaccine Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified38%
Sales qualified26%
Evaluation12%
Closed-won6%
$9.9KCAC
$44KLTV
4.5:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Human Use Rabies Vaccine Market is a resilient opportunity — $3.38B by 2033, compounding at 3.7%.
TAM · 2025$2.53Btoday
TAM · 2033$3.38Bforecast
CAGR3.7%2027–2033
Cumulative$26.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$3.38BTotal addressable market
SAM$1.29BServiceable available market
SOM$218MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.7% CAGR
Demand compounds through 2033, outpacing GDP across Vaccine Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Vaccine Type moving from early to mainstream — durable secular demand.
Consolidation upside
12+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$3.38BLarge & growingTAM by 2033 at 3.7% CAGR
$1.29BServiceable nowreachable with today’s model
$218MBeachhead winobtainable near-term share
12+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.64BBear2.4% CAGR
$3.38BBase3.7% CAGR
$4.33BBull4.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Indication optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Human Use Rabies Vaccine Market — a $7.39B market by 2033. Plan: grow share from 6.9% to 13.3%.
Market size · 2033$7.39Btotal addressable
Market CAGR8.1%2027–2033
Target share13.3%from 6.9% today
Revenue ambition$983Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.9% | 13.3% | On track |
| Revenue | $459M | $983M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Behind |
| Gross margin | 33.5% | 44.4% | Behind |
| Customer retention | 87.2% | 92.8% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Vaccine Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Indication capability
A defensible second engine — invest in Indication to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Vaccine Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Indication
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $124M capacity & capability investment
- Greenlight bolt-on M&A in Indication
- Authorise North America expansion plan
- Fund R&D program for Vaccine Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossAhead
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Human Use Rabies Vaccine Market conversation — a $7.05B market you can size, segment and defend in minutes.
Market size · 2033$7.05Btotal opportunity
Growth6.0%CAGR to 2033
Addressable buyers1,638+accounts in scope
Typical ROI5.8×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Vaccine Type
Goal Grow share in Vaccine Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.8×return on cost, year one
< 2 mopayback period
$86K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
12+players profiled in this market
Coverage includes
Sanofi PasteurGlaxoSmithKline (GSK)Bharat BiotechSerum Institute of IndiaMerial (now part of Boehringer Ingelheim)Novartis (now part of Sandoz)MundipharmaZydus Cadila+4 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Human Use Rabies Vaccine Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Human Use Rabies Vaccine Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Humanized Liver Mice Model Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportHumanized Mouse & Rat Model Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportHumanoid Robot in Retail and Healthcare Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportHumanoid Robot Lead Screw Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportHumanoid Robot Reducer Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportHumanoid Running Robot Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportHumanoid Smart Robots Market
Humanoid Smart Robots Market is valued at USD 2.35 Billion in 2025 and is expected to reach USD…
$2.4B market · 2025 base year
View reportHumatrope Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportHumectant Metaphosphate Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportHumectant Moisturizers Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportHumectant Wetter Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportHumeral Head Prosthesis Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.